ArticleThe Journal of experimental medicine1999
Antigen-specific signaling by a soluble, dimeric peptide/major histocompatibility complex class II/Fc chimera leading to T helper cell type 2 differentiation.
Article in The Journal of experimental medicine, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 64 citations in OpenAlex.
- Review: Bioengineering strategies to probe T cell mechanobiology.APL bioengineering · 2018Review
- Bioconjugate Strategies for the Induction of Antigen-Specific Tolerance in Autoimmune Diseases.Bioconjugate chemistry · 2018Review
- Action and Traction: Cytoskeletal Control of Receptor Triggering at the Immunological Synapse.Frontiers in immunology · 2016Review
- The dendritic cell cytoskeleton promotes T cell adhesion and activation by constraining ICAM-1 mobility.The Journal of cell biology · 2015Article
- Long-term silencing of autoimmune diabetes and improved life expectancy by a soluble pHLA-DR4 chimera in a newly-humanized NOD/DR4/B7 mouse.Human vaccines & immunotherapeutics · 2014Article
- Effect of viscous drag on multiple receptor-ligand bonds rupture force.Colloids and surfaces. B, Biointerfaces · 2012Article
- A theoretical method to determine unstressed off-rate from multiple bond force spectroscopy.Colloids and surfaces. B, Biointerfaces · 2012Article
- Dimeric MHC-peptides inserted into an immunoglobulin scaffold as new immunotherapeutic agents.Journal of cellular and molecular medicine · 2011Review
- Signaling clusters in the cell membrane.Current opinion in cell biology · 2011Review
- T cell receptor triggering by force.Trends in immunology · 2010Article
- Suppression of ongoing T cell-mediated autoimmunity by peptide-MHC class II dimer vaccination.Journal of immunology (Baltimore, Md. : 1950) · 2009Article
- The receptor deformation model of TCR triggering.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2008Article
- Surface-anchored monomeric agonist pMHCs alone trigger TCR with high sensitivity.PLoS biology · 2008Article
- Multimerized T cell epitopes protect from experimental autoimmune diabetes by inducing dominant tolerance.Proceedings of the National Academy of Sciences of the United States of America · 2007Article
- Strength of multiple parallel biological bonds.Biophysical journal · 2006Article
- Article
- Soluble peptide-MHC monomers cause activation of CD8+ T cells through transfer of the peptide to T cell MHC molecules.Proceedings of the National Academy of Sciences of the United States of America · 2002Article
- T-cell activation by soluble MHC oligomers can be described by a two-parameter binding model.Biophysical journal · 2001Article
- Targeting T lymphocytes for immune monitoring and intervention in autoimmune diabetes.American journal of therapeuticsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interaction between a T cell receptor (TCR) and various ligands, i.e. , anti-TCR antibodies, superantigens, peptides, or altered peptide ligands in the context of major histocompatibility complex (MHC) molecules can trigger different T helper cell (Th) effector functions. Herein, we studied the T cell response induced by a soluble, dimeric peptide/MHC class II chimera, namely hemagglutinin (HA)110-120/I-E(d)alphabeta/Fcgamma2a (DEF). We have previously demonstrated that the soluble DEF molecule binds stably and specifically to HA110-120-specific TCRs expressed by a T cell hybridoma. Administration of DEF in vivo induced differentiation of resting and activated peptide-specific T cells toward a Th2 response, as indicated by the increase of interleukin (IL)-4, IL-10, and specific immunoglobulin (Ig)G1 antibodies and decrease of IL-2, specific IgG2a antibodies, and cytotoxic T lymphocyte activity. In contrast to HA110-120 peptide presented by the DEF molecule to T cells, the nominal synthetic peptide induced a predominant Th1 response, and the PR8 virus-derived HA110-120 peptides induced a mixed Th1/Th2 response. Independent of antigen processing, soluble DEF was almost 2 logs more potent in stimulating cognate T cells than the nominal peptide. Polarization of cognate T cells toward the Th2 response occurred upon interaction of soluble DEF with TCR and CD4 molecules followed by early activation of p56(lck) and ZAP-70 tyrosine kinases, and negative signaling of the signal transducer and activator of transcription (STAT)4 pathway of Th1 differentiation. DEF-like molecules may provide a new tool to study the mechanisms of signaling toward Th2 differentiation and may also provide a potential immunotherapeutic approach to modulate autoreactive T cells toward protective Th2 immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.